Chris H Polman
Overview
Explore the profile of Chris H Polman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
165
Citations
13597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freedman M, Comi G, De Stefano N, Barkhof F, Polman C, Uitdehaag B, et al.
Mult Scler Relat Disord
. 2015 Apr;
3(2):147-55.
PMID: 25878002
The first clinical presentation of multiple sclerosis (MS) is usually a single episode of typical symptoms and signs and is designated a "first clinical demyelinating event" (FCDE) or a "clinically...
2.
Vennegoor A, van Rossum J, Polman C, Wattjes M, Killestein J
Mult Scler
. 2015 Feb;
21(12):1600-3.
PMID: 25662344
The presence of anti-John Cunningham Virus (JCV) antibodies is a risk factor for the development of progressive multifocal leukoencephalopathy (PML) in MS patients treated with natalizumab. It has been suggested...
3.
Tewarie P, Schoonheim M, Schouten D, Polman C, Balk L, Uitdehaag B, et al.
Hum Brain Mapp
. 2014 Oct;
36(2):603-18.
PMID: 25293505
Thalamic atrophy is known to be one of the most important predictors for clinical dysfunction in multiple sclerosis (MS). As the thalamus is highly connected to many cortical areas, this...
4.
Munger K, Kochert K, Simon K, Kappos L, Polman C, Freedman M, et al.
Ann Clin Transl Neurol
. 2014 Oct;
1(8):605-17.
PMID: 25285313
Objective: Some previous studies suggest modest to strong effects of 25-hydroxyvitamin D (25(OH)D) on multiple sclerosis (MS) activity. The objective of this study was to explore the mechanistic rationale that...
5.
Sonder J, Balk L, van der Linden F, Bosma L, Polman C, Uitdehaag B
Mult Scler
. 2014 Sep;
21(14):1865-71.
PMID: 25257617
Background: Assessment of disease impact in multiple sclerosis (MS) is usually driven by information obtained directly from patients using patient-reported outcomes. However, when patients' response in longitudinal studies is less...
6.
Kamm C, Uitdehaag B, Polman C
Eur Neurol
. 2014 Aug;
72(3-4):132-41.
PMID: 25095894
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by demyelination and axonal loss. The etiology of MS is unknown; however, environmental and genetic...
7.
Tewarie P, Steenwijk M, Tijms B, Daams M, Balk L, Stam C, et al.
Hum Brain Mapp
. 2014 Jul;
35(12):5946-61.
PMID: 25053254
Both gray matter atrophy and disruption of functional networks are important predictors for physical disability and cognitive impairment in multiple sclerosis (MS), yet their relationship is poorly understood. Graph theory...
8.
Boeschoten R, Uitdehaag B, van Oppen P, de Groot V, Collette E, Bakker K, et al.
JMIR Res Protoc
. 2014 Jun;
3(2):e29.
PMID: 24902042
Background: In multiple sclerosis (MS) patients, symptoms of anxiety, depression, pain, and cognitive impairment are highly prevalent and contribute to lower wellbeing. As these physical and psychological symptoms of distress...
9.
Lublin F, Reingold S, Cohen J, Cutter G, Soelberg Sorensen P, Thompson A, et al.
Neurology
. 2014 May;
83(3):278-86.
PMID: 24871874
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on...
10.
Kilsdonk I, Lopez-Soriano A, Kuijer J, de Graaf W, Castelijns J, Polman C, et al.
J Neurol
. 2014 Apr;
261(7):1356-64.
PMID: 24777693
Recently, a new MRI technique was developed at 3 Tesla (T), called fluid attenuated inversion recovery* (FLAIR*). In this study, we implemented FLAIR* in an existing MS cohort at 7 ...